Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis

被引:42
作者
Khoury, SJ
Orav, EJ
Guttmann, CRG
Kikinis, R
Jolesz, FA
Weiner, HL
机构
[1] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
关键词
soluble intercellular adhesion molecule 1; soluble tumor necrosis factor receptors; MS; brain MRI;
D O I
10.1212/WNL.53.4.758
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To study the change in serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) and soluble tumor necrosis factor receptors (sTNF-Rs) in MS patients in relation to clinical disease activity and changes on brain MRI. Background: Circulating forms of adhesion molecules or soluble receptors may be released from cells as a consequence of activation and may be useful markers for inflammation. Methods: During a prospective longitudinal study over 1 year, 40 patients with MS underwent frequent imaging of the brain (22 MR images per patient) at the time of blood sampling as well as monthly neurologic examinations, and scoring on Kurtzke's Expanded Disability Status Scale (EDSS) and ambulation index (Al). Results: Patients with relapsing-progressive disease had the highest levels of sICAM-1 whereas patients with progressive disease had the highest levels of sTNF-Rs. Fluctuations in sICAM-1 correlated with the occurrence of attacks in patients with relapsing and relapsing-progressive disease. In patients with relapsing-progressive MS, an increase in sICAM-1 level preceded the appearance of new gadolinium (Gd) enhancing lesions an MRI. In patients with progressive disease, an increase in sTNF-R p55 level preceded the appearance of new Gd enhancing lesions on MRI, whereas a decrease in sICAM-1 levels correlated with the appearance of new Gd enhancing lesions. Conclusions: These results demonstrate a linkage between sICAM-1 and sTNF-R levels and disease activity in MS. Furthermore, patients with progressive disease appear to have a different immunologic stage of disease in which immune changes are tightly linked with changes on MRI. The demonstration of a correlation in individual patients between immunologic events and changes in disease activity has implications for monitoring patients undergoing treatment and for monitoring disease progression.
引用
收藏
页码:758 / 764
页数:7
相关论文
共 43 条
[1]   PATHOLOGY, HISTOCHEMISTRY AND IMMUNOCYTOCHEMISTRY OF LESIONS IN ACUTE MULTIPLE-SCLEROSIS [J].
ADAMS, CWM ;
POSTON, RN ;
BUK, SJ .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1989, 92 (2-3) :291-306
[2]   STABILIZATION OF THE BIOACTIVITY OF TUMOR-NECROSIS-FACTOR BY ITS SOLUBLE RECEPTORS [J].
ADERKA, D ;
ENGELMANN, H ;
MAOR, Y ;
BRAKEBUSCH, C ;
WALLACH, D .
JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) :323-329
[3]   Increased interleukin 12 production in progressive multiple sclerosis: Induction by activated CD4(+) T cells via CD40 ligand [J].
Balashov, KE ;
Smith, DR ;
Khoury, SJ ;
Hafler, DA ;
Weiner, HL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (02) :599-603
[4]   INHIBITION OF T-CELL RESPONSES BY ACTIVATED HUMAN CD8+ T-CELLS IS MEDIATED BY INTERFERON-GAMMA AND IS DEFECTIVE IN CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS [J].
BALASHOV, KE ;
KHOURY, SJ ;
HAFLER, DA ;
WEINER, HL .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (06) :2711-2719
[5]   INCREASED PRODUCTION OF INTERFERON GAMMA AND TUMOR NECROSIS FACTOR PRECEDES CLINICAL MANIFESTATION IN MULTIPLE-SCLEROSIS - DO CYTOKINES TRIGGER OFF EXACERBATIONS [J].
BECK, J ;
RONDOT, P ;
CATINOT, L ;
FALCOFF, E ;
KIRCHNER, H ;
WIETZERBIN, J .
ACTA NEUROLOGICA SCANDINAVICA, 1988, 78 (04) :318-323
[6]   THE ADHESION MOLECULE AND CYTOKINE PROFILE OF MULTIPLE-SCLEROSIS LESIONS [J].
CANNELLA, B ;
RAINE, CS .
ANNALS OF NEUROLOGY, 1995, 37 (04) :424-435
[7]  
Chofflon M, 1992, Eur Cytokine Netw, V3, P523
[8]   Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy [J].
Comabella, M ;
Balashov, K ;
Issazadeh, S ;
Smith, D ;
Weiner, HL ;
Khoury, SJ .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (04) :671-678
[9]   Serum and cerebrospinal fluid levels of soluble adhesion molecules in multiple sclerosis: Predominant intrathecal release of vascular cell adhesion molecule-1 [J].
Droogan, AG ;
McMillan, SA ;
Douglas, JP ;
Hawkins, SA .
JOURNAL OF NEUROIMMUNOLOGY, 1996, 64 (02) :185-191
[10]   Soluble CD8 and ICAM-1 in serum and CSF of MS patients treated with 6-methylprednisolone [J].
Franciotta, D ;
Piccolo, G ;
Zardini, E ;
Bergamaschi, R ;
Cosi, V .
ACTA NEUROLOGICA SCANDINAVICA, 1997, 95 (05) :275-279